XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT), a bioscience accelerator at the leading-edge of the life science industry, is involved in preclinical laboratory work designed to study a variety of psychotropic compounds, including psilocybin, mescaline, LSD, MDMA and DMT. The company also announced that its subsidiary, XPhyto Laboratories Inc., has added the production of mescaline to its psychedelic medicine programs. These psychedelic compounds show promising potential in treating mental conditions because they are known to modulate neurotransmitters such as serotonin and dopamine, which regulate cognition, perception and mood in individuals. Called a leader in innovating psychedelic drugs in a recent article, XPhyto is focused on helping individuals who suffer from mental health disorders, including the 11% of Americans that the U.S. Center for Disease Control (“CDC”) reports have contemplated suicide since the outbreak of the COVID-19 pandemic. The number is similar in the UK. A growing number of studies indicate that psychedelic drugs can be effective in treating chronic and serious forms of depression that typically do not respond to existing treatments. Psychedelics are also being studied for the treatment of drug and alcohol addictions as well as post-traumatic stress disorder (“PTSD”). Raimar Löbenberg, a director at XPhyto Therapeutics, is one of a limited few medical scientists in North America who has gained the necessary government-level clearance to experiment in a university laboratory setting with highly regulated Schedule 1 drugs; psychedelics currently fall into this category. Regarding XPhyto Labs, the addition of mescaline to its medicine programs comes as the substance has shown potential as a treatment for addiction and depression. A Schedule I drug, mescaline is used with traditional Native American religious rituals and ceremonies and its becoming increasingly popular as a supplement to meditation and psychedelic therapy. “Our initial focus is to develop standardised drug formulations with precise, predictable and efficient delivery of their active pharmaceutical ingredients for clinical study and therapeutic use,” said XPhyto director Raimar Löbenberg in the article. “We see a lot of potential therapeutic value in psychedelic compounds for their ability to positively influence neural networks through growth and reorganisation.”
To view the full article and press release, visit https://ibn.fm/pLX1R and https://ibn.fm/c5ukf
About XPhyto Therapeutics Corp.
XPhyto Therapeutics is a bioscience accelerator focused on next-generation drug delivery, diagnostic and new active pharmaceutical ingredient investment opportunities including precision transdermal and oral dissolvable drug formulations; rapid, low-cost infectious disease and oral-health screening tests; and standardization of emerging active pharmaceutical ingredients for neurological applications, including psychedelic compounds and cannabinoids. XPhyto has research and development operations in North America and Europe, with an operational focus in Germany, and the company is currently focused on regulatory approval and commercialization of medical products for European markets. For more information about this company, please visit www.XPhyto.com
NOTE TO INVESTORS: The latest news and updates relating to XPHYF are available in the company’s newsroom at https://ibn.fm/XPHYF
About MissionIRNewsBreaks
MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.
MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
[email protected]
Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html
